These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Hobbach HP; Schuster P Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467 [TBL] [Abstract][Full Text] [Related]
5. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720 [TBL] [Abstract][Full Text] [Related]
6. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients. Lavi S; Gruberg L; Kapeliovich M; Hammerman H; Boulos M; Grenadier E; Aronson D; Markiewicz W; Beyar R J Invasive Cardiol; 2005 Jun; 17(6):296-9. PubMed ID: 16003002 [TBL] [Abstract][Full Text] [Related]
7. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466 [TBL] [Abstract][Full Text] [Related]
8. [Antithrombotic treatment of acute coronary syndromes without ST-segment elevation]. Radke PW; Schunkert H Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S204-7. PubMed ID: 17109249 [No Abstract] [Full Text] [Related]
9. Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction. Ben-Yehuda O J Am Coll Cardiol; 2006 Feb; 47(3):538-40. PubMed ID: 16458132 [No Abstract] [Full Text] [Related]
10. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists]. Araujo R; Agustí A Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849 [No Abstract] [Full Text] [Related]
11. The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide. Moliterno DJ; Ziada KM J Am Coll Cardiol; 2008 Feb; 51(5):536-7. PubMed ID: 18237681 [No Abstract] [Full Text] [Related]
12. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
14. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty]. Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204 [TBL] [Abstract][Full Text] [Related]
15. Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors. Maioli M; Zeymer U; van 't Hof AW; Gibson CM; Dudek D; Bellandi F; Noc M; Secco GG; Zorman S; Gabriel HM; Emre A; Cutlip D; Rakowski T; Gyongyosi M; Huber K; De Luca G; J Invasive Cardiol; 2012 Jul; 24(7):324-7. PubMed ID: 22781470 [TBL] [Abstract][Full Text] [Related]
16. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years? Silva MA; Gandhi PJ J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937 [TBL] [Abstract][Full Text] [Related]
17. ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy. Boden WE; Hoekstra J; Miller CD Am J Emerg Med; 2008 Feb; 26(2):212-20. PubMed ID: 18272105 [TBL] [Abstract][Full Text] [Related]
19. Mechanical reperfusion: treat well, treat on time too. Montalescot G Lancet; 2008 Aug; 372(9638):509-10. PubMed ID: 18707968 [No Abstract] [Full Text] [Related]
20. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]